PD-1 inhibitors are successfully used in the treatment of patients with advanced melanoma, and it has been shown that the occurrence of ICI-induced irTAEs appears to be related to improved antineoplastic efficacy [13–15]. This evidence concerns the gene PDCD1 and melanoma.